Cargando…

Single-Shot Ad26 Vaccine Protects Against SARS-CoV-2 in Rhesus Macaques

A safe and effective vaccine for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) may be required to end the coronavirus disease 2019 (COVID-19) pandemic(1–8). For global deployment and pandemic control, a vaccine that requires only a single immunization would be optimal. Here we show th...

Descripción completa

Detalles Bibliográficos
Autores principales: Mercado, Noe B., Zahn, Roland, Wegmann, Frank, Loos, Carolin, Chandrashekar, Abishek, Yu, Jingyou, Liu, Jinyan, Peter, Lauren, McMahan, Katherine, Tostanoski, Lisa H., He, Xuan, Martinez, David R., Rutten, Lucy, Bos, Rinke, van Manen, Danielle, Vellinga, Jort, Custers, Jerome, Langedijk, Johannes P., Kwaks, Ted, Bakkers, Mark J.G., Zuijdgeest, David, Huber, Sietske K. Rosendahl, Atyeo, Caroline, Fischinger, Stephanie, Burke, John S., Feldman, Jared, Hauser, Blake M., Caradonna, Timothy M., Bondzie, Esther A., Dagotto, Gabriel, Gebre, Makda S., Hoffman, Emily, Jacob-Dolan, Catherine, Kirilova, Marinela, Li, Zhenfeng, Lin, Zijin, Mahrokhian, Shant H., Maxfield, Lori F., Nampanya, Felix, Nityanandam, Ramya, Nkolola, Joseph P., Patel, Shivani, Ventura, John D., Verrington, Kaylee, Wan, Huahua, Pessaint, Laurent, Van Ry, Alex, Blade, Kelvin, Strasbaugh, Amanda, Cabus, Mehtap, Brown, Renita, Cook, Anthony, Zouantchangadou, Serge, Teow, Elyse, Andersen, Hanne, Lewis, Mark G., Cai, Yongfei, Chen, Bing, Schmidt, Aaron G., Reeves, R. Keith, Baric, Ralph S., Lauffenburger, Douglas A., Alter, Galit, Stoffels, Paul, Mammen, Mathai, Van Hoof, Johan, Schuitemaker, Hanneke, Barouch, Dan H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7581548/
https://www.ncbi.nlm.nih.gov/pubmed/32731257
http://dx.doi.org/10.1038/s41586-020-2607-z
Descripción
Sumario:A safe and effective vaccine for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) may be required to end the coronavirus disease 2019 (COVID-19) pandemic(1–8). For global deployment and pandemic control, a vaccine that requires only a single immunization would be optimal. Here we show the immunogenicity and protective efficacy of a single dose of adenovirus serotype 26 (Ad26) vector-based vaccines expressing the SARS-CoV-2 spike (S) protein in nonhuman primates. 52 rhesus macaques were immunized with Ad26 vectors encoding S variants or sham control and were challenged with SARS-CoV-2 by the intranasal and intratracheal routes(9,10). The optimal Ad26 vaccine induced robust neutralizing antibody responses and provided complete or near-complete protection in bronchoalveolar lavage and nasal swabs following SARS-CoV-2 challenge. Vaccine-elicited neutralizing antibody titers correlated with protective efficacy, suggesting an immune correlate of protection. These data demonstrate robust single-shot vaccine protection against SARS-CoV-2 in nonhuman primates. The optimal Ad26 vector-based vaccine for SARS-CoV-2, termed Ad26.COV2.S, is currently being evaluated in clinical trials.